Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.

According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

A number of other research firms have also weighed in on DRNA. ValuEngine raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright dropped their price objective on Dicerna Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, April 10th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $7.00 price objective (down previously from $8.00) on shares of Dicerna Pharmaceuticals in a research note on Sunday, April 2nd. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 9th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.88.

Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up 0.48% during mid-day trading on Monday, hitting $4.15. The company’s stock had a trading volume of 379,045 shares. The stock’s market cap is $86.30 million. Dicerna Pharmaceuticals has a 52-week low of $2.42 and a 52-week high of $6.10. The company’s 50 day moving average is $3.18 and its 200-day moving average is $3.02.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.03. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.08 million. On average, equities analysts predict that Dicerna Pharmaceuticals will post ($2.31) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Lifted to “Hold” at Zacks Investment Research” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/24/dicerna-pharmaceuticals-inc-nasdaqdrna-lifted-to-hold-at-zacks-investment-research.html.

Institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co raised its position in shares of Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 53,131 shares during the last quarter. Sabby Management LLC raised its position in shares of Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 100,000 shares during the last quarter. UBS Group AG raised its position in shares of Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock worth $968,000 after buying an additional 1,599 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Dicerna Pharmaceuticals by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 408,682 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 84,682 shares during the last quarter. Finally, Palo Alto Investors LLC raised its position in shares of Dicerna Pharmaceuticals by 204.2% in the first quarter. Palo Alto Investors LLC now owns 481,519 shares of the biopharmaceutical company’s stock worth $1,637,000 after buying an additional 323,240 shares during the last quarter. 55.81% of the stock is owned by institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.